Figure 2.
Figure 2. Best nodal response to treatment with idelalisib and ofatumumab in evaluable patients. Best nodal response for 24 patients evaluable for lymph node response (3 patients were not evaluable: 1 because of lack of baseline adenopathy and 2 because of short duration of treatment without follow-up scans before receiving the next line of therapy). Blue bars represent patients with TP53 aberrant disease. SPD, sum of the products of the perpendicular diameters of measured lymph nodes.

Best nodal response to treatment with idelalisib and ofatumumab in evaluable patients. Best nodal response for 24 patients evaluable for lymph node response (3 patients were not evaluable: 1 because of lack of baseline adenopathy and 2 because of short duration of treatment without follow-up scans before receiving the next line of therapy). Blue bars represent patients with TP53 aberrant disease. SPD, sum of the products of the perpendicular diameters of measured lymph nodes.

Close Modal

or Create an Account

Close Modal
Close Modal